2122 § These authors contributed equally to this work. 23 24 33 and phenobarbital was discontinued. After 10 days of cessation, the patient had normal SAA, 34 and clinical signs were resolved. 35 36 37 pseudolymphoma 38 39 130 reported in veterinary medicine, and this report could serve as a valuable reference for the 131 diagnosis and treatment of feline AHS using serum SAA and anticonvulsant concentrations.

No abstract

Background Since mesenchymal stem cells (MSCs) possess regenerative and immunomodulatory properties, and are capable of controlling the immune dysregulation that leads to β-cell destruction, stem cell transplantation could be used in the management of insulin-dependent diabetes mellitus (IDDM). In this pilot study, we assessed whether canine adipose tissue-derived MSC (cAT-MSC) therapy could be an option for treatment of canine diabetes mellitus. Results With the written informed consent of the owners, allogenic cAT-MSCs were infused intravenously in IDDM dogs. C-peptide was elevated by about 5–15% in 3 of 4 cases, and hyperlipidemia was resolved in 2 of 4 cases. Additionally, fructosamine and Hb/A1c levels were improved in 2 of 4 cases. Conclusions Considering that C-peptide secretion capacity and lipid metabolism are related to diabetic complications, these results suggest that cAT-MSC therapy in diabetic dogs might help to improve the insulin secretory capacity of dogs with IDDM and prevent diabetic complications.